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Background: Quantitative real-time (q)PCR for detection of minimal residual disease (MRD)
in children with neuroblastoma (NB) can evaluate molecular bone marrow (BM) response to
therapy, but the prognostic value of tumour kinetics in the BM during induction treatment
remains to be established. The purpose of this study was to analyse at which time points
MRD detection by sequential molecular assessment of BM was prognostic for overall sur-
vival (OS).
Methods: In this single centre study, qPCR was performed with five NB-specific markers:
PHOX2B, TH, DDC, GAP43 and CHRNA3, on 106 retrospectively analysed BM samples of 53
patients >1 year with stage 4 neuroblastoma. The prognostic impact of MRD at diagnosis
(n = 39), at 3 months after diagnosis (n = 38) and after completing induction chemotherapy
(n = 29) was assessed using univariate and bivariate Cox regression analyses.
Results: There was no correlation between tumour load at diagnosis and outcome (p = 0.93).
Molecular BM remission was observed in 11/38 (29%) of patients at 3 months after diagnosis
and associated with favourable outcome (5-y-OS 62 ± 15.0% versus 19 ± 8%; p = 0.009). After
completion of induction chemotherapy, BM of 41% (12/29) of the patients was still MRD
positive, which was associated with poor outcome (5-y-OS 0% versus 52 ± 12%; p < 0.001).
For both time points, the prognostic value of molecular response remained significant in
bivariate analysis.
Conclusions: MRD detection measured by a panel of NB specific-PCR targets could identify
fast responders, who clear their BM early during treatment. Fast molecular response was
a prognostic factor, associated with better outcome. Our data indicate that MRD analysis
during induction therapy should be included in prospective MRD studies.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction survival rate of only 30–40%.1 Especially bone marrow (BM)Neuroblastoma (NB) is the most common extra-cranial solid
neoplasm in children. More than 50% of the patients present
with metastasis at the time of diagnosis, with a 5-yearn 125, 1066 CX Amsterda
.nl (C.E. van der Schoot).
the Elsevier OA license.involvement is very common in children with metastatic dis-
ease detected by standard morphologic examination. Detec-
tion of tumour cells by quantitative real-time (q)PCR with a
panel of neuroblastoma specific RNA markers was shown tom, The Netherlands. Tel.: +31 20 5123377; fax: +31 20 5123474.
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nique reliably detects tumour cells with a sensitivity of 1 in
106 normal nucleated bone marrow cells.2,3 Currently, overall
response evaluation is based on the International Neuroblas-
toma Response Criteria (INRC),4 in which results on BM cytol-
ogy, MIBG scintigraphy, urinary catecholamine excretion and
imaging (echo/MRI) are combined to assess the extent of dis-
ease. However, detection of minimal residual disease (MRD) in
BM and/or peripheral blood (PB) using qPCR could be more
significant for therapy response evaluation. Sensitive MRD
measures for early response to therapy might predict ulti-
mate response and survival. Identification of patients with
resistant tumours shortly after the start of therapy would en-
able a choice for alternative treatments and might improve
survival rates.
Although MRD using qPCR is widely studied in neuroblas-
toma, still little information is available on the correlation of
MRD at different time points during treatment with clinical
outcome. Evaluation of tumour cell content in BM during
therapy using immunocytology has shown to provide impor-
tant prognostic information in metastatic NB.5 In addition,
there is increasing evidence that also MRD PCR markers can
be useful for the evaluation of therapeutic response.6–8
The purpose of this study was to determine whether
sequential molecular MRD assessment of bone marrow dur-
ing the first year of therapy was prognostic for ultimate over-
all survival (OS). We report here the correlation between
outcome and bone marrow MRD status measured by a panel
of NB-specific PCR targets, for all assessable BM samples of
patients with metastatic high risk neuroblastoma treated be-
tween 1991 and 2006 in the Emma’s Children Hospital in the
Netherlands.
2. Material and methods
2.1. Patients and samples
In this retrospective study we investigated archived BM sam-
ples from children older than 1 year of age, diagnosed with
stage 4 neuroblastoma staged according to the International
Neuroblastoma Staging System (INSS),4 treated at the Emma
Children’s Hospital/AMC (Amsterdam, The Netherlands) be-
tween 1991 and 2006. In total, 106 BM samples were collected
from 53 patients at the following time points; 39 at diagnosis;
38 at mid induction (3 months after diagnosis; range 2–
4 months) and 29 at end induction (median 8 months after
diagnosis, range 6–12 months), see Table 1. We have previ-
ously extensively shown that all BM samples positive with
cytology at diagnosis are also positive by qPCR,2,9 so for the
analyses at mid- and end-induction patients with BM disease
detected by cytology and/or qPCR at diagnosis were included.
Data extracted from the medical record included dates of
diagnosis and death, MYCN gene copy number, results of
bone marrow aspirates and biopsies, 123I-meta-iodobenzyl-
guanidine (123I-MIBG) scan, ultrasound, CT scan or MRI scan,
and urine catecholamine metabolites (homovanillic acid
(HVA) and 4-hydroxy-3-methoxymandelic acid (HMM), for-
merly named vanilmandelic acid (VMA). Disease status at
mid induction and end induction was scored according to
the International Neuroblastoma Response Criteria (INRC).4Written informed consent was obtained from parents or
guardians. The study was approved by the Medical Research
Ethics Committee of the AMC.
2.2. Therapy
Patients were treated according to consecutive protocols used
at the Emma Children’s Hospital/AMC, Amsterdam, in the
Netherlands; these protocols used the following induction
chemotherapy: VECI10 (n = 36), rapid-COJEC11 (n = 7) or
GPOH-NB9712 (n = 10). Prior to induction chemotherapy, a
majority of patients received (1–4) infusions of 131I-MIBG
(n = 36) as described before.10 In 7 patients infusions of 131I-
MIBG were directly followed by Topotecan (n = 7). In all proto-
cols patients were treated with myeloablative chemotherapy
(MAT) and re-infusion of autologous bone marrow (n = 16) or
peripheral blood stem cells (n = 17), if they had CR or VGPR,
followed by 13-cis-retinoic acid therapy.1
2.3. RNA extraction, reverse transcription and
quantitative real-time PCR
Cells were isolated by haemolysis (NH4Cl) within 24 h after
collection in EDTA tubes. Cells were counted and aliquoted
per 5 * 106 in 0.5 ml RNABee. Total cellular RNAwas extracted
with RNABee method according to manufacturer’s instruc-
tions (Campro Scientific, Veenendaal, the Netherlands). RNA
concentration and quality were determined using an ND-
1000 spectrophotometer (Nanodrop, Wilmington, USA). cDNA
was synthesised as described previously.2qPCR for paired-like
homeobox2b (PHOX2B), tyrosine hydroxylase (TH), dopamine
decarbohydroxylase (DDC), cholinergic receptor3 (CHRNA3)
and growth associated protein 43 (GAP43) was performed in
an ABI PRISM 7900 (PE Biosystems, Darmstadt, Germany) as
described before.2,9 Reference gene beta-glucuronidase (GUS)
was used for normalisation (normalised Ct (DCt) = Ct GUS ) Ct
marker), because it was stably expressed in all NB tumours
tested (data not shown) and because its expression in NB
was equal to that in haematologic cells.13 The number of
GUS-copies was determined using GUS-plasmid DNA (Ipso-
gen, Marseille, France) dilutions. All qPCR experiments were
carried out at least in duplicate and mean values were used.
An IMR32 calibration curve was used as an exogenous posi-
tive control to ascertain the efficiency of each PCR reaction.
2.4. Data analysis
Marker positivity has been described previously.2 In short,
clinical samples were scored positive if PHOX2B Ctsample < 50
or if one of the other markers had a mean DCTsample > 3.0 Ct
of DCtcontrol BM. Thus if one of the markers was scored positive
the samples were scored as positive. Thresholds for positivity
(DCtcontrol BM) were determined in BM samples from 51 chil-
dren in molecular remission of acute lymphoblastic leukae-
mia9 and depicted in supplementary Table 1.
2.5. Statistical analysis
Correlation analysis was done using scatterplot and
Spearman’s test. Overall survival was calculated using the
Table 1 – Sample origin.
Patient nr. Treatment protocol Diagnosis Mid induction End induction 5-year OS (months) Died
60 VECI x x 60 0
64 VECI x x 13 1
65 VECI x 8 1
81a VECI x 60 0
82 VECI x 19 1
93 VECI x 4 1
166 VECI x x 60 0
168 VECI x 14 1
248 VECI x 5 1
249 VECI x 4 1
341a VECI x 41 1
406 VECI x x 8 1
407 VECI x 60 0
410 VECI x x 60 0
415 VECI x x x 12 1
418 VECI x x 60 0
425 VECI x x 41 1
430 VECI x x x 10 1
442 VECI x x 12 1
458 VECI x x 7 1
462 VECI x x 60 0
479 VECI x x 16 1
483a VECI x 60 0
489 VECI x x x 7 1
490 VECI x x x 18 1
492 VECI x x 19 1
511 VECI x x 60 0
519 VECI x x 7 1
538 VECI x x x 11 1
539 VECI x 47 1
540 VECI x x x 9 1
557 VECI x x 12 1
559 VECI x x 11 1
576 VECI x x x 46 1
583 VECI x x 6 1
593 VECI x x x 60 0
594 Rapid-COJEC x x x 60 0
597 Rapid-COJEC x 25 1
599 Rapid-COJEC x x 9 1
600 Rapid-COJEC x x x 14 1
604 Rapid-COJEC x x 20 1
620 Rapid-COJEC x x 58 0
621 Rapid-COJEC x x x 56 0
622 GPOH-NB97 x 19 1
627 GPOH-NB97 x x 10 1
628 GPOH-NB97 x x 6 1
630 GPOH-NB97 x x 54 0
635a GPOH-NB97 x 50 0
638 GPOH-NB97 x x 9 1
642 GPOH-NB97 x x x 29 1
649 GPOH-NB97 x x x 41 0
652 GPOH-NB97 x x 41 0
661 GPOH-NB97 x x x 19 1
Total sample 39 38 29
Abbreviations: VECI, vincristine, ifosfamide, carboplatin, etoposide; OS, overall survival in months; died, 0, alive; 1, died.
a Patient with RQ-PCR negative BM at diagnosis. These patient’s samples were not included in further analyses regarding therapy response of
BM disease.
E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 1 1 9 3 –1 2 0 2 1195Kaplan–Meier method and survival curves were compared
using log-rank statistics. Due to small patient numbers,
bivariate Cox models were used to assess the independence
of predictive information coming from BM qPCR relative toother prognostic factors and response indicators. Only fac-
tors, which were significant in univariate analyses, were as-
sessed in bivariate analyses. All statistics were done using
SPSS 15.0.
Table 2 – Characteristics of stage 4 neuroblastoma patients
>1 year of age (n = 53).
Characteristic p-Valuea
Age at diagnosis 0.19
Median (months) 30
Range 12–162
<18 months of age 8
>18 months of age 45
MYCN 0.07
Amplified 18
Not amplified 35
BM cytology 0.30
Positive 46
Negative 7
Urinary catecholamines 0.06
Positive 50
Negative 3
MIBG scan initial diagnosis
MIBG uptake by primary tumour 0.17
Positive 49
Negative 4
MIBG uptake by BM/bone metastasis 0.32
Positive 44
Negative 9
BM qPCR 0.10
Positive 35
Negative 4
Missing 14
Treatment
MIBG therapy 0.37
MIBG upfront 36
MIBG + topotecan upfront 7
No MIBG upfront 10
Protocol 0.60
VECI 36
rCOJEC 7
GPOH-NB97 10
Autologous stem cell transplantation 0.50
BM 19
No reinfusionb 3
PBSC 23
No reinfusionb 6
No harvestb 11
Overall survival after 5 years
Median percentage 33.4
Std error 6.6
Observation time
Median (months) 116
Range 36–256
a Log rank test.
b No harvest or reinfusion of graft due to progressive disease.
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3.1. Patients’ characteristics
The median age at initial diagnosis of all 53 stage 4 neuroblas-
toma patients was 2.5 years (range 1.0– 3.5 years), and the
median observation time was 9.6 years (range 3–21 years) (Ta-
ble 2). At diagnosis all patients had BM or distant bone metas-
tases determined by BM cytology (n = 46), MIBG scintigraphy
(n = 6) and/or bone scintigraphy (n = 1). The 5 year overall sur-
vival was 33.4 ± 6.6%. No difference in outcomewas found be-
tween patients treated with the different protocols for
induction chemotherapy (p = 0.60), patients treated with or
without MIBG infusions (p = 0.37) and patients reinfused with
autologous BM or PBSC grafts (p = 0.50). Furthermore, MYCN
status, positivity of urine catecholamine metabolites, MIBG
and/or BM cytology at diagnosis had no significant bearing
on outcome, see for p-values Table 2.
3.2. Results of quantitative real-time PCR
Of the 106 archived BM samples from 53 stage 4 patients; 39
samples collected at diagnosis were available; 38 at mid
induction and 29 at end induction. Of this series of 106 BM
samples, 74 tested positive by molecular analyses. PHOX2B
was the most sensitive marker and was detected in 72 of
the 74 positive samples, see Fig. 1.
At diagnosis 4 of the samples from 39 patients were nega-
tive with all qPCR markers. These patients also had negative
BM cytology andwere not included in further analyses regard-
ing therapy response of BM disease. PHOX2B was the only
marker that was positive in all 35 positive samples (data not
shown).
In BM at 3 months (range 2–4) after start of therapy, 27 of
the 38 samples tested positive for MRD. Of these 27 positive
samples, 26 were at least positive for PHOX2B, while one sam-
ple was only positive for TH.
In BM after completion of induction chemotherapy, 12 of
the 29 samples were MRD positive. One sample was only po-
sitive for CHRNA3, while 11 samples were at least positive for
PHOX2B.
3.3. Outcome according to tumour load in BM at diagnosis
Fig. 2 shows that tumour load at diagnosis, as defined by the
normalised expression of PHOX2B (Ct GUS ) Ct PHOX2B) in
BM, did not correlate to survival (p = 0.93). This was also found
for the other markers (data not shown). Of the 4 patients
without BM involvement at diagnosis measured with qPCR,
3 patients are still alivewith a median follow up of 80 months.
The other patient died of progressive disease 52 months after
diagnosis, see for survival curves Fig. 3a.
3.4. Outcome according to MRD status 3 months after
diagnosis
To identify fast molecular responders, we analysed MRD sta-
tus 3 months (range 2–4) after start of therapy of patients with
BM positive disease at diagnosis. Twenty-seven of the 38 pa-
tients (71%) had MRD positive BM, so 11 patients (29%) didnot have detectable MRD in the BM anymore. The patients
with a fast molecular response had significantly better sur-
vival than patients, who still had MRD positive BM at that
time (5-y-OS of 62.3 ± 15.0% versus 18.5 ± 7.5%, log rank test
p = 0.009, see Fig. 3b). Partial response (PR) was also associated
with better outcome compared to a mixed response (MR) or
no response (NR), in univariate analysis. The other clinical
1PHOX2B
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CHRNA3
DDCGAP43
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32
Fig. 1 – Value of markers in MRD detection. A total 106 BM
samples were tested with a panel of five qPCR markers. Each
ellipse represents positive results of one marker. The
number outside the ellipses represents the samples which
were negative for all five markers (n = 32).
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catecholamine response and presence of residual MIBG posi-
tive metastasis, were not significantly associated with out-
come. In bivariate analysis with INRC response, molecular
response remained significantly associated with survival
(p = 0.05) (Table 3), indicating that qPCR can give information,
which cannot be obtained with the currently used response
parameters in predicting survival. Fifteen of 27 MRD positive
patients never reached VGPR and progressed before autolo-
gous harvest or stem cell reinfusion could be performed.
Results of individual markers were not prognostic for out-
come, except for PHOX2B (5-y-OS of 57.3 ± 14.6% versus
19.2 ± 7.7%, log rank test p = 0.011). However, with the use of
a panel of markers, one more positive sample was identified,
therefore, the panel was more prognostic for outcome
(p = 0.009).
Of the whole cohort of 53 patients there were 29 that could
be analysed with five markers both at diagnosis and at mid-
induction. The levels at diagnosis were not significantly dif-
ferent for patients with or without a fast molecular response
(supplementary Fig. 1).-15
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Fig. 2 – Correlation between tumour load at diagnosis and surviv
with months survival, a cut-off at 60 months after diagnosis wa3.5. Outcome according to MRD status after completing
induction chemotherapy
After completionof induction chemotherapy,MRDwas still de-
tected in BM of 12 of the 29 (41%) patients. All patients with
MRD positive BM died of progressive disease, while the 5-
y-OS for patients with MRD negative BM was 52.3 ± 12.3%,
Fig. 3c (log rank test, p < 0.001). Partial response, presence of
residual 123I-MIBG positive metastasis, positive BM cytology
and the presence of urinary metabolites were also univariate
significantly associated with poor survival. These results indi-
cate that, residual disease present (especially in the BM) after
the completion of induction therapy is indicative for resistant
or progressive disease. qPCR remained significantly associated
with survivalwhencorrected for theotherprognostic factors in
separate (bivariate)models (Table 4).These results suggest that
qPCR after completing of induction therapy can give additional
information to currently used clinical parameters for assess-
ment of disease status. For example, cytology detectedNB cells
in five BM samples, while qPCR detected 12 positive samples.
Furthermore,qPCR identified3extrapatientswith residualdis-
ease, who were in CR according to INRC. The other patients
withMRDpositiveBMnever reachedVGPRandhadprogressive
disease before autologous harvest and/or stem cell reinfusion
could beperformed.Again at this timepoint a panel ofmarkers
identified more positive samples than individual markers. As
an illustration, TH detected MRD in 6, PHOX2B in 11 and the
panel of markers in 12 BM samples.
3.6. Sequential MRD analysis
BM samples of both follow-up time points (mid induction and
after completion of induction chemotherapy) were available
of 19 patients. Six patients were MRD negative at both time
points (fast responders), 7 patients were positive at the first
time point and negative after completing induction chemo-
therapy (slow responders) and 6 patients were still MRD posi-
tive after induction chemotherapy (non-responders).
Although this cohort was very small, the survival curve indi-
cates that patients in the first group with a fast molecular BM
response had a better survival than patients in the other two40 50 60
l (months)
alive
died
R 2 = 0.0006
p=0.93
al. Normalised expression of PHOX2B is shown in correlation
s set (Spearman’s test, p = 0.93).
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Fig. 3 – MRD detection at different time points during treatment is correlated with outcome. Survival curves according to MRD
status at 3 months after diagnosis (a) at 3 months after diagnosis (b) and after completion of induction chemotherapy (c)
(dotted curve, MRD positive patient; black curve, MRD negative patients).
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log rank test p = 0.001) (Fig. 4).
The levels of marker expression at all three time points
were available from 14 of 19 patients. Representative exam-
ples of three patients, a fast responder, a slow responder
and a non-responder are shown in Fig. 5 (for all 19 patients
see supplementary Fig. 2). Although there were differences
in MRD positivity between markers, the variation between
the markers was not extensive and the changes with time
were similar for the five PCR targets.Table 3 – Measurements of response to treatment: Univariate an
patients tested by qPCR at 3 months after start of induction the
Univariate analysis p
qPCR (positive versus negative)
INRC response (CR/VGPR/PR versus MR/NR)
MIBG status (positive residual versus negative)
Catecholamine metabolites (CR/VGPR versus PR/MR/NR)
Cytology (positive versus negative)
Bivariate analysisa
qPCR (positive versus negative)
INRC response (CR/VGPR/PR versus MR/NR)
All parameters are compared at diagnosis versus after 3 months therapy
Abbreviations: INRC, International Neuroblastoma Response Criteria; CR
response; NR, no response.
a Only factors significant in univariate analyses were assessed in bivaria4. Discussion
In this study we have shown that sequential molecular MRD
assessment of bone marrow is a prognostic factor for ulti-
mate overall survival. We investigated this by measuring
molecular bone marrow infiltration at (1) diagnosis, (2) early
during treatment and (3) after completion of induction ther-
apy. We found that a fast molecular response (BM negative
by qPCR at mid induction) was associated with better out-
come, compared to slow molecular response (BM negatived bivariate Cox regression analyses of survival factors, for all
rapy (n = 38).
-Value Hazard ratio 95% CI of the hazard ratio
0.009 4.2 1.4–12.4
0.04 2.9 1.1–7.7
0.37 1.46 0.6–3.3
0.26 1.9 0.6–5.5
0.12 2.0 0.8–4.6
0.05 3.3 1.0–10.8
0.38 1.7 0.58–5.0
.
, complete remission; VGPR, very good partial response; MR, mixed
te analyses.
Table 4 – Measurements of response to treatment: Univariate and bivariate Cox regression analyses of survival factors, for all
patients tested by qPCR after completion of induction therapy (n = 29)
Univariate analysis p-Value Hazard ratio 95% CI of the hazard ratio
qPCR (positive versus negative) <0.001 6.0 2.2–16.2
INRC response (CR/VGPR versus PR/MR/NR) 0.03 2.7 1.1–6.8
MIBG status (positive residual versus negative) 0.04 2.6 1.1–6.6
Catecholamines metabolates (CR versus VGPR/PR/MR/NR) 0.001 5.8 2.0–17.3
Cytology (positive versus negative) <0.001 14.4 3.6–57.6
Bivariate analysisa
qPCR (positive versus negative) 0.003 5.1 1.8–14.8
INRC response (CR/VGPR versus PR/MR/NR) 0.35 1.6 0.6–4.4
qPCR (positive versus negative) 0.003 4.8 1.7–13.6
MIBG status (positive residual versus negative) 0.25 1.8 0.7–4.8
qPCR (positive versus negative) 0.05 3.3 1.0–11.3
Catecholamine metabolites (CR versus VGPR/PR/MR/NR) 0.11 2.7 0.8–9.7
qPCR (positive versus negative) 0.007 4.5 1.5–13.4
Cytology (positive versus negative) 0.01 6.5 1.5–27.2
All parameters are compared at diagnosis versus after completion of induction therapy.
Abbreviations: INRC, International Neuroblastoma Response Criteria; CR, complete remission; VGPR, very good partial response; MR, mixed
response; NR, no response.
a Only factors significant in univariate analyses were assessed in bivariate analyses.
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Fig. 4 – Sequential MRD analysis identifies fast responders.
Fast responders were defined as MRD negative at 3 months
after start of therapy and MRD negative after induction
chemotherapy; slow responders were defined as MRD
positive at 3 months after start of therapy and MRD negative
after induction completion of chemotherapy; no molecular
remission was defined as MRD positive 3 months after start
of therapy and MRD positive after completion of induction
chemotherapy (blackcurve, fast responders; grey curve, slow
responders; dotted curve, no molecular BM remission dur-
ing treatment).
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induction therapy.
The results can be of great translational value, even
though the patient cohort described was small and not uni-
formly treated nor all treated according to treatment proto-
cols employed today. In the light of our results, it might be
possible to stratify patients based on MRD results already in
the first months after diagnosis, independent of the treat-
ment protocol. Also in acute lymphoblastic leukaemia it has
been shown that an early molecular response is prognostic
for outcome, regardless of the treatment protocol used.14 Of
course our results need to be confirmed in prospective MRDstudies with uniformly treated patients. However, at this mo-
ment early time points are not included in most prospective
MRD studies, as recommended by the International Neuro-
blastoma Risk Group Task Force.15
A number of authors have applied MRD detection by qPCR
in PB or BM to assess the effect of induction chemother-
apy,7,8,16 adjuvant therapy6 or total treatment16–18 and to de-
tect relapse.8,19 The most commonly used markers in these
studies were TH and GD2 synthase (GD2S). However, the use
of TH and GD2S as MRD markers in neuroblastoma is ham-
pered by their expression in normal BM, PB and/or PBSC. Pre-
viously, we have identified the marker PHOX2B, which is
exquisitely neuroblastoma specific using the primer-probe
set described2 although using a different primer-probe set a
single amplification in 1 out of 50 control PB/BM samples
has been encountered by Viprey et al.20 In addition, we de-
scribed that a panel of markers is more sensitive for detection
of MRD than the use of PHOX2B alone.9 GD2Swas not included
in that panel, because of lower specificity and sensitivity than
the other markers. Here we show that MRD detection in bone
marrow with this panel of five qPCR markers is both clinically
relevant and significantly associated with outcome. When we
performed survival analysis per individual marker, PHOX2B
was most significant for predicting outcome at both time
points. Although the increase in detection of positive samples
using a panel of five markers was minimal, TH and CHRNA3
identified 2 more patients with MRD positive BM that both
died of progressive disease. On the one hand this further cor-
roborates the superiority of applying a panel of markers com-
pared to a single marker. However, on the other hand, the
costs and use of the amount of sample are higher when using
a panel of markers. So, our ongoing prospective study will
show which markers will be needed for optimal MRD detec-
tion. Therefore, we advise to use next to PHOX2B at least
one other marker, e.g. TH for MRD detection.
For the evaluation of the clinical relevance of MRD detec-
tion, we first determined whether the level of bone marrow
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Fig. 5 – Normalised expression of 5 PCR markers at diagnosis, mid induction and end induction. Representative examples of a
fast responder (a), slow responder (b) and a non-responder (c) are shown. Abbreviations: BM, bone marrow; background,
normalised expression equal to control bone marrow samples. Patients are anonymised using N + patient number.
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did not find a difference in BM tumour load between patients
who succumbed or survived. It has been suggested by Trager
and colleagues21 that high expression of TH at diagnosis cor-
responds to poor outcome. However, in their study all high
risk neuroblastoma patients, including patients without
metastasis with MYCN amplification, were selected, whereas
we only tested BM of patients with stage 4 with bone or BM
disease at diagnosis. In addition, different cut-off levels for
defining MRD positivity were used, making it difficult to com-
pare results between our study and the study of Trager and
colleagues However, in both studies it seems that high tu-
mour load at diagnosis is not correlated to survival. This sug-
gests that the mere presence of BM infiltration is the major
prognostic factor rather than the level of infiltration.
Secondly, we investigated whether the kinetics of molecu-
lar BM response to chemotherapy related to outcome. We first
looked at the MRD status at 3 months after diagnosis and
found that the absence of MRD was significantly associatedwith overall survival and remained significantly associated
when tested in a bivariate model with INRC response. Only
a few other studies investigated the impact of early clearance
of BM MRD on outcome.5,7,8 Using immunocytology, Seegers
and colleagues5 found that patients with more than
100 cells/105 in the BM after three cycles of induction chemo-
therapy had poor survival. However, in their study the num-
ber of MRD positive patients was only 6% compared to 71%
in this study, because the level of detection was one tumour
cell in 103 normal cells. In our study the level of detection
for MRD positivity is one tumour cell in 106 normal cells.9
Consequently, they identified patients resistant to therapy
rather than the fast responders that we identified. Using TH
as a marker, two small cohort studies also showed in univar-
iate analysis that MRD detection with qPCR at 3–4 months
after diagnosis was associated with poor outcomes.7,8 Fukuda
and colleagues7 found that 6/21 (29%) patients had TH nega-
tive BM 4months after diagnosis and none of these patients
died. In the second study, Tchirkov and colleagues8 found that
E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 1 1 9 3 –1 2 0 2 120111/22 patients, with less than 1000 TH transcripts in the BM
after three cycles of induction chemotherapy had a signifi-
cantly better survival. However, both studies did not investi-
gate the association of PCR results with other clinical
response parameters.
In addition to the early time point, we also tested molecu-
lar response after completion of induction chemotherapy, and
found that the presence of BM MRD was associated with poor
outcome. In fact all patients whose BM was MRD positive
after completion of induction therapy, ultimately died from
their disease. We could not perform complete bivariate anal-
ysis which included all prognostic variables, because of the
small sample size and performed, therefore, combined (bivar-
iate) analysis only. In the combined analysis with INRC re-
sponse, the presence of MRD after completion of induction
chemotherapy remained significantly associated with sur-
vival. Three of 12 MRD positive patients were thought to be
in CR, which strongly suggests that minimal residual disease
can contribute to disease progression. Hence, our study
shows that BM qPCR can give information, which cannot be
obtained with the currently used clinical parameters for
assessment of disease status such as INRC response.
In 20 out of 53 patients BM/PBSCs were not infused, be-
cause of the progression of disease. As can be expected none
of these patients were fast responders, and of those analysed
after induction chemotherapy one was a slow responder and
all the others were non-responders. We are aware that most
of these patients were treatedwith low intense chemotherapy
and dose intense induction chemotherapy, which is now
being used,22 will probably result in more fast responders,
which is currently being investigated in a prospective study.
Our patient cohort did not receive adjuvant immunotherapy,
so possibly more slow or non responders could have become
MRD negative as described by Cheung and colleagues.6,16
They showedwith GD2S qPCR that patients with MRD positive
BM before immunotherapy, who became MRD negative after
two cycles of immunotherapy had a significantly better out-
come than non-responders to immunotherapy. In addition
they showed by using PHOX2B for MRD detection that almost
all patients with BM positive disease after chemotherapy and
two cycles of immunotherapy died of progressive disease,23
which is in line with our results.
In only a limited number of patients (n = 19) MRD could be
assessed at the two consecutive time points. Despite the
small size of this study and the variation in treatment proto-
cols, our results indicate that, based on the kinetics in treat-
ment response, three patient groups (within the high risk
group) can be identified with different prognosis (Fig. 4); an
extremely high risk group with no molecular BM remission,
a very high risk group with slow molecular BM response
(molecular remission post induction) and a high risk group
with a fast molecular BM response already in molecular
remission after 3 months of therapy. In addition, a very small
group has stage 4 disease without measurable BM invasion,
which also might have a better response to HR treatment.
We conclude that MRD detection as measured by a panel
of NB specific-PCR targets, constituted by PHOX2B, TH and
CHRNA3, can identify fast responders, who clear their BM
early during treatment. Early molecular response seems to
be a prognostic factor associated with better outcomes. Ourresults indicate that it might be possible to stratify patients
based on MRD results already in the first months after diagno-
sis. PCR guided therapy might result in better survival rates by
early identification of patients who might benefit from con-
ventional treatment and early identification of patients who
need different (new) therapies. To verify the results of this
small heterogeneous retrospective study, we strongly recom-
mend including time points during induction therapy in pro-
spective MRD studies.
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